A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A
at 6 month
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CBHQ880A2204
NCT01302886
May 2011
October 2013
Name | Location |
---|---|
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) | Atlanta, Georgia 30322 |
Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville, Arkansas 72703 |
H. Lee Moffitt Cancer Center/University of South Florida SC - 3 | Tampa, Florida 33612 |
Indiana University Indiana Univ | Indianapolis, Indiana 46202 |
Dana Farber Cancer Institute DFCI (2) | Boston, Massachusetts 02115 |
Washington University School Of Medicine-Siteman Cancer Ctr Dept. of WUSTL | St. Louis, Missouri 63110 |
Hackensack University Medical Center Multiple Myeloma Division | Hackensack, New Jersey 07601 |
Mount Sinai School of Medicine Mt Sinai | New York, New York 10029 |
Duke University Medical Center Duke SC | Durham, North Carolina 27710 |
Fred Hutchinson Cancer Research Center Fred Hutchinson | Seattle, Washington 98109 |